Pharmistry Consulting Limited 09799172 false 2023-10-01 2024-09-30 2024-09-30 The principal activity of the company is the provision of consultancy services to the pharmaceutical industry. Digita Accounts Production Advanced 6.30.9574.0 true 09799172 2023-10-01 2024-09-30 09799172 2024-09-30 09799172 core:RetainedEarningsAccumulatedLosses 2024-09-30 09799172 core:ShareCapital 2024-09-30 09799172 core:CurrentFinancialInstruments 2024-09-30 09799172 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 09799172 core:OfficeEquipment 2024-09-30 09799172 bus:SmallEntities 2023-10-01 2024-09-30 09799172 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 09799172 bus:FilletedAccounts 2023-10-01 2024-09-30 09799172 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 09799172 bus:RegisteredOffice 2023-10-01 2024-09-30 09799172 bus:Director1 2023-10-01 2024-09-30 09799172 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 09799172 core:OfficeEquipment 2023-10-01 2024-09-30 09799172 countries:EnglandWales 2023-10-01 2024-09-30 09799172 2023-09-30 09799172 core:OfficeEquipment 2023-09-30 09799172 2022-10-01 2023-09-30 09799172 2023-09-30 09799172 core:RetainedEarningsAccumulatedLosses 2023-09-30 09799172 core:ShareCapital 2023-09-30 09799172 core:CurrentFinancialInstruments 2023-09-30 09799172 core:CurrentFinancialInstruments core:WithinOneYear 2023-09-30 09799172 core:OfficeEquipment 2023-09-30 iso4217:GBP xbrli:pure

Registration number: 09799172

Pharmistry Consulting Limited
 

Annual Report and Unaudited Financial Statements- Companies house filing

for the Year Ended 30 September 2024

 

Pharmistry Consulting Limited

(Registration number: 09799172)
Statement of Financial Position as at 30 September 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

1,054

1,406

Current assets

 

Debtors

5

694

921

Cash at bank and in hand

 

635,093

538,022

 

635,787

538,943

Creditors: Amounts falling due within one year

6

(54,992)

(30,869)

Net current assets

 

580,795

508,074

Total assets less current liabilities

 

581,849

509,480

Provisions for liabilities

(200)

(267)

Net assets

 

581,649

509,213

Capital and reserves

 

Called up share capital

100

100

Profit and loss account

581,549

509,113

Shareholders' funds

 

581,649

509,213

For the financial year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Income Statement.

Approved and authorised by the director on 21 March 2025
 

.........................................
Miss V S Mistry
Director

 

Pharmistry Consulting Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is: Knoll House, Knoll Road, Camberley, Surrey, GU15 3SY, England.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable services rendered, net of discounts and Value Added Tax.

Revenue from the rendering of services is measured by references to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be reliably estimated. When the outcome cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

 

Pharmistry Consulting Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2024

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office Equipment

Reducing balance - 25%

Trade debtors

Short term debtors are measured at transaction price, less any impairment.

Cash and cash equivalents

Cash is represented by cash in hand and bank deposits.

Trade creditors

Short term creditors are measured at the transaction price.

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Employee benefits

Short-term employee benefits are recognised as an expense in the period which they are incurred.

Financial instruments

The Company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

 

Pharmistry Consulting Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 September 2024

4

Tangible assets

Office equipment
£

Total
£

Cost or valuation

At 1 October 2023

3,533

3,533

At 30 September 2024

3,533

3,533

Depreciation

At 1 October 2023

2,127

2,127

Charge for the year

352

352

At 30 September 2024

2,479

2,479

Carrying amount

At 30 September 2024

1,054

1,054

At 30 September 2023

1,406

1,406

5

Debtors

2024
£

2023
£

Prepayments

694

921

694

921

6

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Taxation and social security

45,638

22,966

Accruals and deferred income

3,743

3,216

Other creditors

5,611

4,687

54,992

30,869